PT-141 (Bremelanotide)

PT-141 (Bremelanotide) is a melanocortin receptor agonist used for sexual enhancement. Unlike PDE5 inhibitors, it works in the brain to increase arousal and libido. It is FDA-approved for female sexual dysfunction and used off-label in men to improve sexual function without affecting vascular systems.

• Activates melanocortin-4 receptor (MC4R) in the central nervous system
• Stimulates dopamine release and arousal pathways in hypothalamus
• Enhances libido by bypassing peripheral vascular signaling
• Independent of nitric oxide, making it viable for patients with cardiovascular risks

• unit: mg

  low dose: 0.75

  frequency: Use as needed ~45 minutes before sexual activity; max 1x per 24h

  high dose: 1.75

  standard dose: 1.75

  administration route: Subcutaneous (SQ)

• Use as needed, max once per day. Not intended for continuous daily use. Effects peak 45–90 min post-injection.

common: ["Transient BP elevation (~6/3 mmHg, peaks at 4 hours, returns baseline by 8–10 hours)","Skin hyperpigmentation with repeated use"]

sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

half life: 2.5 hours

degradation: Cleared via hepatic and renal metabolism

molecular weight: 1025.2

molecular formula: C50H68N14O10

tissue specificity: CNS arousal centers: hypothalamus, brainstem

• Bremelanotide: First Approval.reviewPMID 31429064 ↗
• An evaluation of bremelanotide injection for hypoactive sexual desire disorder.reviewPMID 36242769 ↗